Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine Dosing Strategies in Major Depression
NCT00191061Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of duloxetine in major depressive disorder (MDD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Incidence of treatment-emergent nausea and Efficacy in non-responders. Started Oct 2004; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00191061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191061.